🏥 Oncology Advances: Radium-223, Pembrolizumab, Cabozantinib, 225Ac-Satoreotide, Amivantamab — and more
This week’s edition of Oncology Research and Treatment Updates covers new combination therapies, immunotherapy breakthroughs, and FDA approvals that are shaping the future of oncology.
Clinical Trial & Research Insights:
📌 Radium-223 Combination Therapy – A study at City of Hope evaluates radium-223, hormone therapy, and SBRT to target micrometastatic disease while minimizing long-term side effects.
📌 Pembrolizumab in Gynecologic Cancer – A 42 percent disease control rate was observed at 12 weeks, with a median overall survival of 14.8 months.
📌 Cabozantinib and Nivolumab in MSS mCRC – A phase 2 trial reports a 40 percent disease control rate, with a median overall survival of 10.9 months. 📌 Envafolimab in Colorectal Cancer – Shows a 25 percent objective response rate and 90 percent disease control rate, with no dose-limiting toxicities.
📌 225Ac-Satoreotide for Small Cell Lung Cancer – The upcoming SANTANA-225 trial will evaluate this radiopharmaceutical’s safety and efficacy.
📌 Gemogenovatucel-T for Ovarian Cancer – The VITAL trial demonstrated a 92 percent two-year overall survival rate, leading to FDA RMAT designation.
📌 Serplulimab for ES-SCLC – Approved in the European Union, based on ASTRUM-005 trial data, showing a median overall survival of 15.4 months.
📌 Subcutaneous Amivantamab – A faster, equally effective alternative to intravenous administration, backed by PALOMA-3 trial data.
🔔 Stay Updated with LucidQuest!
🔔 Like, share, and subscribe to stay ahead of the latest in oncology research.
💡 Looking for expert analysis on oncology trends? Contact LucidQuest at info@lqventures.com for expert insights.
#LucidQuest #Oncology #CancerResearch #ClinicalTrials #ProstateCancer #LungCancer #ColorectalCancer #OvarianCancer #Immunotherapy #FDAApproval #MedicalInnovation 🚀